Selective serotonin reuptake inhibitors

Millions to gain access to Psychedelic Psychotherapy in bid to fight pandemic induced depression and anxiety

Retrieved on:

Thursday, June 17, 2021

Psychoactive drugs, Selective serotonin reuptake inhibitors, Drugs, Antidepressants, Chemical compounds, Serotonin reuptake inhibitor, Fluoxetine, Citalopram, Escitalopram, Development and discovery of SSRI drugs, Management of depression

Launched today for the first time Journey Clinical provides self-employed psychotherapists and independent practices the necessary access to a prescriber to offer ketamine-assisted psychotherapy (KAP) to patients.

Key Points:

Launched today for the first time Journey Clinical provides self-employed psychotherapists and independent practices the necessary access to a prescriber to offer ketamine-assisted psychotherapy (KAP) to patients.
One-in-ten Americans are taking anti-depressant medication with the majority taking selective serotonin reuptake inhibitors (SSRIs) such as Prozac, Celexa and Lexapro.
However an increasing number of people believe anxiety and depression stems from internalised trauma which SSRIs fail to tackle.
The pandemic has exacerbated the mental health crisis, with some 100 million now estimated to be dealing with depression today.

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Retrieved on:

Friday, May 21, 2021

RBX2660 demonstrated superior efficacy versus placebo (70.4% and 58.1%, respectively) at 8 weeks post treatment, with a comparable safety profile to placebo.

Key Points:

RBX2660 demonstrated superior efficacy versus placebo (70.4% and 58.1%, respectively) at 8 weeks post treatment, with a comparable safety profile to placebo.
In addition to these outcomes, RBX2660 provided a relative reduction of recurrence of 29.4% compared to placebo.
The majority of treatment emergent adverse events (TEAEs) for RBX2660 were similar to placebo, and mild to moderate in nature.
difficile infection is a global public health threat that requires immediate action to halt the unrelenting cycle of recurrence.

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

Retrieved on:

Tuesday, April 27, 2021

Major depressive disorder, Antidepressants, Chloroarenes, Selective serotonin reuptake inhibitors

Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.

Key Points:

Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.
In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Global Antidepressants Market Report 2021: COVID-19 Causes a Surge in Demand for Antidepressant Drugs as Mental Health Problems Rise - ResearchAndMarkets.com

Retrieved on:

Monday, April 26, 2021

Pharmaceutical, Health, Mental health, Selective serotonin reuptake inhibitors, Antidepressants, Chemical compounds, Psychoactive drugs, Organic compounds, Major depressive disorder, Escitalopram, Citalopram, Management of depression

Therefore, rising cases of mental health disorders is expected to drive the growth of the antidepressant market.\nThe side-effects of antidepressant drugs is a key factor hampering the growth of the antidepressant market.

Key Points:

Therefore, rising cases of mental health disorders is expected to drive the growth of the antidepressant market.\nThe side-effects of antidepressant drugs is a key factor hampering the growth of the antidepressant market.
For instance, the antidepressants Lexapro (escitalopram) and Celexa (citalopram), both are used to treat depression and Lexapro also helps for treating anxiety.
People who are already living with mental health problems are experiencing increased stress levels over the COVID-19 outbreak.
This has triggered the demand for antidepressant drugs.\nThe treatment for resistant depression is a key trend in the antidepressant market.

Selective Serotonin Reuptake Inhibitors (SSRIs) Market- AbbVie Inc., Apotex Inc., Aurobindo Pharma Ltd., among others to contribute to the market growth|Industry Analysis, Market Trends, Opportunities and Forecast 2025

Retrieved on:

Friday, April 2, 2021

Selective serotonin reuptake inhibitors, Pharmacology, Branches of biology, Drugs, Serotonin reuptake inhibitor, Serotonin, Reuptake inhibitor, Serotonin–norepinephrine reuptake inhibitor, Allosteric serotonin reuptake inhibitor

The selective serotonin reuptake inhibitors (SSRIs) market is poised to grow by $ 809.73 mnduring 2021-2025, progressing at a CAGR ofabout 4% during the forecast period.

Key Points:

The selective serotonin reuptake inhibitors (SSRIs) market is poised to grow by $ 809.73 mnduring 2021-2025, progressing at a CAGR ofabout 4% during the forecast period.
The report on the selective serotonin reuptake inhibitors (SSRIs) market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
This study identifies the growing geriatric population as one of the prime reasons driving the selective serotonin reuptake inhibitors (SSRIs) market growth during the next few years.
The selective serotonin reuptake inhibitors (SSRIs) market covers the following areas:

Do Commonly Prescribed Antidepressants Increase the Risk of Bleeding Stroke?

Retrieved on:

Wednesday, March 3, 2021

Psychoactive drugs, Drugs, Chemical compounds, Selective serotonin reuptake inhibitors, Antidepressant, Serotonin, Serotonin–norepinephrine reuptake inhibitor, Serotonin–norepinephrine–dopamine reuptake inhibitor

MINNEAPOLIS, March 3, 2021 /PRNewswire/ --There is good news for people who take antidepressants called selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants in the United States.

Key Points:

MINNEAPOLIS, March 3, 2021 /PRNewswire/ --There is good news for people who take antidepressants called selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed antidepressants in the United States.
The most common causes are high blood pressure and head trauma, but some studies have also suggested that SSRIs may increase a person's risk of this type of bleeding stroke.
"However, by interfering with serotonin, which also plays a role in blood clotting, SSRIs may increase the risk of bleeding.
Therefore, to determine if these antidepressants increase the risk of bleeding strokes, we looked at a large population of people with stroke."

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

Retrieved on:

Monday, February 8, 2021

Chemical compounds, RTT, Selective serotonin reuptake inhibitors, Chemistry, Organic compounds, Genomics, Pharmacogenomics, Pharmacology, Pharmacy, Escitalopram, Citalopram

SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.

Key Points:

SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.
Using data from the Genomics Used to Improve DEpression Decisions (GUIDED) randomized-controlled trial, the study evaluated the ability of the combinatorial approach available in the GeneSight Psychotropic test to predict patient outcomes and medication blood levels compared to Clinical Pharmacogenetics Implementation Consortium(CPIC) single-gene recommendations.
Medication Blood Levels The analysis of the combinatorial pharmacogenomic test and single-gene guidelines showed the predictive ability of the GeneSight combinatorial approach was better.
This is the second study evaluating the combinatorial approach of the GeneSight test to be published inPsychiatry Research.The earlier study, published in May 2020, demonstrated the combinatorial approach available in the GeneSight Psychotropic test was better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.

New report describes positive results of generic drug in treating COVID

Retrieved on:

Monday, February 1, 2021

Selective serotonin reuptake inhibitors, Antidepressants, Health sciences, Occupational safety and health, Ethers, Fluvoxamine, Psychoactive drugs, Health, Coronavirus disease

"Repurposed drugs always have had the potential to be the fastest and least expensive way out of this pandemic.

Key Points:

"Repurposed drugs always have had the potential to be the fastest and least expensive way out of this pandemic.
In this study, fluvoxamine was again shown to be 100% effective in the early treatment of COVID.''
In addition, after two weeks, none of the treatment group had any COVID symptoms while 60% of the group who declined the drug had one or more COVID symptoms.
CETF is funding a Phase 3 clinical trial to examine the efficacy of using fluvoxamine for the early treatment of COVID.

Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder

Retrieved on:

Wednesday, December 9, 2020

Branches of biology, Medical specialties, Clinical medicine, Selective serotonin reuptake inhibitors, Psychiatric diagnosis, Immunology, Borderline personality disorder, Suicidal ideation, Major depressive disorder, Inflammation, Fluoxetine, Suicide

Surprisingly, QuadraMune administration appeared superior to Prozac at stimulating proliferation of new brain cells.

Key Points:

Surprisingly, QuadraMune administration appeared superior to Prozac at stimulating proliferation of new brain cells.
"Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune for preventing suicide."
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.
Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder.

Fluvoxamine Data Unveiled as Promising Early Treatment in Patients with Mild COVID-19

Retrieved on:

Tuesday, October 6, 2020

Health, Articles, Selective serotonin reuptake inhibitors, Clinical research, Pharmaceutical industry, Ethers, Fluvoxamine, Drug discovery, Clinical trial, Coronavirus disease, COVID-19 drug repurposing research, COVID-19 drug development

The trial results indicated that fluvoxamine, if given early in the course of COVID-19, significantly reduced the likelihood of hospitalization.

Key Points:

The trial results indicated that fluvoxamine, if given early in the course of COVID-19, significantly reduced the likelihood of hospitalization.
Fluvoxamine a repurposed drug has been around since 1983 and could prevent COVID-19 patients from developing more severe symptoms.
COVID-19 Early Treatment Fund is the sole or primary sponsor of several other clinical trials that are led by leading scientific researchers.
Once funded, outpatient trials could identify an effective early treatment within just a few months.